Thermo Fisher Scientific Inc. $TMO Stock Sold by Bell Asset Management Ltd

Key Points

• Bell Asset Management cut its Thermo Fisher stake by 73.2% in the third quarter, selling 8,835 shares and retaining 3,242 shares valued at approximately $2.19 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported a strong latest quarter, with EPS of $6.03 and revenue of $11.99 billion, exceeding estimates and representing 10.5% year-over-year revenue growth. The company’s FY 2026 EPS guidance is $24.93–$25.33.
• Analyst sentiment remains mixed: the stock carries a “Moderate Buy” consensus with a $634.86 price target, while recent downgrades and substantial insider selling—including sales by the CEO—highlight valuation and profit-taking concerns.

Bell Asset Management Ltd lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 73.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,242 shares of the medical research company's stock after selling 8,835 shares during the quarter. Bell Asset Management Ltd's holdings in Thermo Fisher Scientific were worth $2,189,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $15,501,867,000. State Street Corp increased its stake in shares of Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock worth $9,633,991,000 after acquiring an additional 229,630 shares during the period. Corient Private Wealth LP acquired a new stake in Thermo Fisher Scientific in the second quarter valued at about $382,547,000. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $1,974,561,000. Finally, Bank of America Corp DE acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $1,952,930,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher helped launch the Digital CMC Consortium, bringing biopharma companies, technology providers and regulators together to establish digital standards for chemistry, manufacturing and controls data. The initiative could support faster drug development, more efficient regulatory reviews and recurring digital lifecycle-management opportunities. What Could Thermo Fisher Scientific Change With Its New Digital CMC Consortium?
• Positive Sentiment: Thermo Fisher’s clinical research business signed an agreement with Quantum BioPharma to support a Phase 2 multiple sclerosis trial for Lucid-MS. The contract reinforces demand for the company’s contract research services, although the near-term financial impact was not disclosed. Quantum BioPharma Enlists Thermo Fisher’s Clinical Research Business
• Neutral Sentiment: Industry reports project strong long-term growth in pharmaceutical contract research, PCR testing and cell-based assay markets, where Thermo Fisher is a major participant. These reports improve the sector’s growth backdrop but do not represent new company guidance or orders. Pharmaceutical CRO Market Forecasts Growth PCR Market Report Forecasts Growth
• Negative Sentiment: Profit-taking is likely after a strong rally supported by Thermo Fisher’s prior earnings beat. With the next results approaching, investors may be waiting for confirmation that biopharma and laboratory spending remain strong enough to justify the stock’s elevated valuation.
• Negative Sentiment: Quiver Quantitative reported that insiders made no open-market purchases and recorded 94 sales over the past six months, including substantial sales by senior executives. Recent analyst price targets cited in the report were generally below the prevailing share price, which may reinforce valuation concerns. The data should be interpreted cautiously because insider sales can reflect compensation and diversification.

Thermo Fisher Scientific Price Performance

TMO stock opened at $651.63 on Friday. The stock has a 50-day moving average price of $625.73 and a two-hundred day moving average price of $540.54. The company has a market cap of $240.94 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.77 and a beta of 0.87. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $694.33.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 EPS. The company's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on TMO. Scotiabank began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an "outperform" rating for the company. BMO Capital Markets cut Thermo Fisher Scientific to a "market perform" rating in a report on Wednesday, September 9th. Wells Fargo & Company cut Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a report on Wednesday, September 9th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $634.86.

Insider Buying and Selling

In related news, VP Lisa P. Britt sold 11,440 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.